Zyn Sold to Teens as “Tobacco-Free” While Hiding Addiction Risks — Lawsuits Explained

Philip Morris International and its subsidiary Swedish Match North America face a growing wave of lawsuits over Zyn nicotine pouches, the smokeless product that captured 70 percent of the U.S. nicotine pouch market while building a viral following among teenagers on social media. Plaintiffs in federal and state courts allege that the companies marketed Zyn with false “tobacco-free” labeling, targeted underage consumers with flavored products and social media influencer campaigns, and sold a product engineered for high nicotine absorption without adequate warnings about the risk of severe addiction.

The litigation spans multiple fronts: proposed consumer class actions challenging the “tobacco-free” label as false advertising, personal injury suits from adults who became addicted as minors, and a municipal enforcement action filed by the City of Baltimore. A first trial in the personal injury track is scheduled for December 7, 2026, in the U.S. District Court for the Southern District of Florida. The FDA authorized Zyn’s marketing in January 2025, a ruling defendants cite in their defense, but that authorization has not stopped courts from allowing the lawsuits to proceed.

Zyn Lawsuit Timeline and Updates

2014 — Zyn Enters the U.S. Market

Swedish Match introduced Zyn nicotine pouches to the United States in 2014, positioning the product as a discreet, smoke-free, spit-free alternative to cigarettes and traditional smokeless tobacco. The pouches are small white packets placed between the upper lip and gum, where nicotine is absorbed through the oral mucosa directly into the bloodstream. They contain nicotine, food-grade fillers, flavoring agents, and pH adjusters, but no tobacco leaf.

The “tobacco-free” label became central to Zyn’s marketing identity. It implied, to many consumers, a product substantially safer and less harmful than tobacco. Lawsuits would later allege that the claim is misleading because Zyn’s nicotine is derived from tobacco through extraction, not synthesized, and that the extraction process leaves behind tobacco-associated compounds, including trace amounts of carcinogenic tobacco-specific nitrosamines.

2019 — Bailey Wolters Begins Using Zyn as a Teenager

Bailey Wolters, a California resident, began using Zyn nicotine pouches around 2019 at the age of approximately 16. His experience would later form the basis of one of the first class action lawsuits filed against Swedish Match and Philip Morris International. According to his complaint, filed March 1, 2024, in the U.S. District Court for the Eastern District of California, Wolters developed a nicotine addiction as a direct result of Zyn’s youth-targeted marketing, which led him to believe the products were not tobacco-derived and did not carry significant addiction risk.

January 2024 — Senate Majority Leader Chuck Schumer Calls for Federal Action

Senate Majority Leader Chuck Schumer held a press conference calling on the Food and Drug Administration and the Federal Trade Commission to investigate Zyn’s marketing and health effects. Schumer described Zyn as “a pouch packed with problems” and stated that the product appeared to “lock its sights on young kids, teenagers and even lower, and then use social media to hook them.” His comments drew a sharp partisan reaction, with several Republican lawmakers publicly defending Zyn, but the Senate’s attention accelerated regulatory and litigation scrutiny of the product.

The political debate crystallized around the “Zynfluencer” phenomenon: social media personalities on TikTok, YouTube, and Instagram who had built audiences partly around Zyn content, often using humor, lifestyle imagery, and catchphrases that appealed to young audiences. The hashtag #Zynbabwe, a play on the country name, had accumulated millions of views. Philip Morris International denied authorizing influencer campaigns and stated that its marketing guidelines prohibit the use of social media influencers, but the organic spread of Zyn content online had created an enormous, youth-saturated promotional environment regardless.

March 2024 — First Major Class Action Filed

The first major proposed class action lawsuit against Swedish Match and Philip Morris International was filed in March 2024 on behalf of a class of U.S. consumers who purchased Zyn products. The 35-page complaint alleged that the companies marketed Zyn as “tobacco-free” while knowing the nicotine was extracted from tobacco leaves, that Zyn pouches contain chemical compounds characteristic of tobacco-derived products, and that the companies deliberately targeted teenagers and young adults with packaging resembling mint containers, gum-like candy flavors such as wintergreen, peppermint, spearmint, and cinnamon, and advertising built around youth lifestyle themes.

The complaint described Zyn as “just a recent iteration of the tobacco industry’s historical practice of designing a nicotine delivery device that hooks kids to nicotine while making them think it is not dangerous or harmful.” It drew a direct line from Philip Morris International’s decades of Marlboro marketing to a new generation of nicotine products under new labeling, but using the same strategy: make the product seem cool, approachable, and safe, especially to people who do not yet use nicotine.

April 2024 — Personal Injury Lawsuit Filed by Florida Teen Who Became Addicted

Alannah Friedman, a young Florida woman, filed a personal injury lawsuit against Philip Morris International, Swedish Match North America, Swedish Match USA, Philip Morris Global Brands, and PMI Global Services in the U.S. District Court for the Southern District of Florida. Friedman alleged that she began using Zyn at age 17 after encountering Zyn’s social media marketing, which she said led her to believe the product was not a tobacco-derived item and would not be harmful to her health.

According to the complaint, Friedman became addicted to nicotine through Zyn use and has suffered personal injuries as a result, including continued compulsive dependence on the pouches. She alleged that Zyn’s use of “Zynfluencers,” youth-oriented flavors, packaging designed to resemble mint containers, and hashtags like #Zynbabwe constituted a deliberate campaign to recruit underage users. The lawsuit is one of the first individual personal injury suits against Zyn to be scheduled for trial.

October 2023 to February 2024 — FDA Issues 160+ Warning Letters to Retailers

The FDA Center for Tobacco Products issued more than 119 warning letters and 41 civil penalty complaints to brick-and-mortar and online retailers caught selling Zyn to consumers under 21 years old. The enforcement actions confirmed that underage sales were occurring at scale despite the legal age restriction. They also provided litigation ammunition for plaintiffs arguing that Zyn’s marketing and distribution practices facilitated access by minors.

January 16, 2025 — FDA Authorizes Zyn Marketing

The FDA authorized the marketing of 20 Zyn nicotine pouch products under the Premarket Tobacco Product Application process, making Zyn the first and only authorized nicotine pouch product in the United States. The FDA’s evaluation found that Zyn products “pose a lower risk of cancer and other serious health conditions than cigarettes and most smokeless tobacco products” and that the benefits of marketing the products to adult smokers as a switching tool outweigh the risks given the currently low rate of youth use.

The authorization was not a finding that Zyn is safe. The FDA explicitly stated the products remain addictive and that the authorization does not constitute FDA approval. The agency noted that the 2024 National Youth Tobacco Survey found 1.8 percent of middle and high school students, approximately 480,000, reported using nicotine pouches, with high school use rising from 3 percent to 6 percent year over year. The FDA conditioned authorization on Philip Morris marketing only to adults 21 and older, using models or actors no younger than 35, and avoiding themes or imagery that appeal to youth. Senate Democrats Richard Blumenthal and Jeff Merkley wrote to the FDA in December 2025 expressing concern that the agency’s review process had not adequately accounted for rising youth use rates.

March 2024 — Eastern District of California Class Action Filed

A separate proposed class action was filed in the U.S. District Court for the Eastern District of California on behalf of John Doe, a consumer who alleged he purchased Zyn believing it was a safer, healthier alternative to cigarettes. The complaint raised overlapping allegations: deceptive “tobacco-free” advertising, failure to disclose that Zyn contains TSNAs and other tobacco-derived compounds, and inadequate warnings about nicotine addiction risk.

March 19, 2025 — Florida Federal Judge Allows Key Claims to Proceed

U.S. District Judge William P. Dimitrouleas issued a significant ruling in two consumer class action lawsuits, Zachary Kelly v. Philip Morris International and Kovadis Palmer v. Philip Morris International, partially granting and partially denying the defendants’ motion to dismiss. The judge dismissed one claim of fraudulent concealment for lacking sufficient detail but allowed the core deceptive marketing and product liability claims to proceed. The ruling rejected Philip Morris’s argument that the “tobacco-free” advertising claims could not support a deceptive trade practices case under Florida law.

The ruling cleared the way for discovery and potential class certification in the Florida class actions, marking the first substantive judicial endorsement that Zyn’s labeling and marketing practices raise viable legal claims.

May 5, 2025 — Friedman Personal Injury Trial Scheduled for December 2026

Judge Dimitrouleas issued a scheduling order in the Friedman personal injury case setting trial for December 7, 2026, and directing both parties to complete mediation before that date. The order set a discovery cutoff of June 26, 2026, and required all pretrial motions, including Daubert challenges to expert witnesses, to be filed by July 24, 2026. The mediation requirement signals that the court is giving the parties a structured opportunity to settle before trial.

May 7, 2025 — City of Baltimore Files Zyn Lawsuit

The Mayor and City Council of Baltimore filed suit against Philip Morris International, Swedish Match North America, and Swedish Match USA in Baltimore Circuit Court under the city’s Consumer Protection Ordinance. The complaint alleged that the companies deceptively marketed Zyn to children and teenagers in Baltimore through flavored products, packaging designed to appeal to youth, and social media campaigns. The city sought civil penalties and injunctive relief, framing the case as a public health enforcement action against youth nicotine marketing in a city where adolescent addiction rates had drawn official concern.

Baltimore’s complaint cited medical expert findings that nicotine use by minors can impair brain development, elevate anxiety and depression, increase long-term cardiovascular disease risk, and cause oral injuries from prolonged mucosal contact with nicotine pouches.

September 2025 — Siegert False Advertising Class Action Filed in Connecticut

A proposed class action, Siegert v. Swedish Match North America et al., was filed in the U.S. District Court for the District of Connecticut in September 2025. The complaint focused specifically on the false advertising dimension of Zyn’s labeling. Plaintiffs alleged that Zyn’s nicotine is tobacco-derived, not synthetic, making the “tobacco-free” claim false, that TSNAs including NNN (N-Nitrosonornicotine) and NNK have been detected in Zyn pouches in scientific studies, that Zyn pouches are engineered for higher nicotine bioavailability than cigarettes due to the elevated pH of the oral delivery mechanism, and that the “tobacco-free” claim deceived consumers who paid a price premium based on perceived reduced risk.

December 2025 — Florida Judge Refuses to Dismiss Deceptive Trade Claim

A federal judge in Florida refused to dismiss the deceptive business practices claim in the Zyn litigation, ruling that the allegations were sufficient to survive a motion to dismiss under Florida’s Deceptive and Unfair Trade Practices Act. The court rejected Philip Morris’s argument that the deceptive trade claim was a disguised fraud claim requiring heightened pleading. The ruling kept a critical state consumer protection cause of action alive through the next phase of litigation.

What Zyn Actually Contains — and Why “Tobacco-Free” Is Contested

The central scientific dispute in the Zyn litigation is whether the label “tobacco-free” is accurate, and if so, whether it is nonetheless misleading.

Zyn pouches do not contain tobacco leaf. That fact is undisputed. The product’s nicotine, however, is extracted from tobacco plants using a purification process. Plaintiffs in the false advertising cases argue that because the nicotine is derived from tobacco rather than synthesized chemically, the product is not genuinely “tobacco-free” in any meaningful sense, and that trace compounds left over from the extraction process confirm tobacco origin.

Scientific studies referenced in the complaints found several tobacco-associated compounds in Zyn pouches:

Philip Morris and Swedish Match dispute the significance of these findings, arguing the detected levels are trace amounts far below thresholds associated with health risk. The FDA’s January 2025 authorization supports their position to a degree: the agency determined Zyn poses substantially lower cancer risk than combustible tobacco and most smokeless tobacco products. However, the FDA authorization does not address whether the “tobacco-free” label is accurate or misleading as a matter of consumer protection law, which is what the lawsuits center on.

A peer-reviewed study published in Tobacco Control in 2022 analyzed 46 nicotine pouch products across 20 brands and detected TSNAs in many samples. A separate clinical study found that in 118 adult nicotine pouch users, nearly half had visible oral lesions. Research on snus users, who place similar products in the same oral location, found that roughly 20 percent of young users developed gum recession. Because Zyn delivers nicotine through the same mucosal route with the same physical placement, researchers expect analogous long-term oral health outcomes.

The “Zynfluencer” Marketing Machine and Youth Targeting Allegations

Plaintiffs across all the Zyn lawsuits identify the “Zynfluencer” phenomenon as the most direct evidence of deliberate youth marketing. Zyn’s viral social media spread did not happen organically. Content creators on TikTok, YouTube, and Instagram built substantial followings around Zyn content, often depicting use as a sophisticated, socially desirable habit. Hashtags like #Zynbabwe, a playful portmanteau that appears in millions of posts, functioned as a brand community identifier with no age gate and no health warning.

Philip Morris International’s official position is that its marketing policies prohibit the use of influencers and that it does not control user-generated content. Lawsuits counter that the company knew Zynfluencer content existed, benefited commercially from the awareness it generated among younger demographics, and failed to take meaningful steps to suppress it or disclaim association with it. The company simultaneously ran its own paid advertising using models in their late 20s participating in active, social settings, imagery that plaintiffs argue was designed to appeal to consumers in their teens and early 20s despite the legal age minimum of 21.

Product design choices also feature prominently in the youth marketing allegations. Zyn’s packaging in round tins resembles the format of mint containers like Altoids, products widely used and purchased by teenagers. Flavor names and profiles, including Cool Mint, Spearmint, Wintergreen, Citrus, Cinnamon, and Coffee, mirror the flavor profiles common to products marketed to adolescents. The complaint in Bailey Wolters’ case alleged that Zyn is designed to “look like chewing gum” to appeal to teenagers who would associate the product with familiar candy-adjacent formats rather than tobacco products.

The 2024 National Youth Tobacco Survey found that among middle and high school students who use nicotine pouches, more than two-thirds named Zyn as their preferred brand. Nicotine pouch use among high school students rose from 3 percent in 2023 to 6 percent in 2024, a doubling in one year. Approximately 480,000 U.S. students in grades 6 through 12 reported current use.

The Nicotine Delivery Mechanism and Why Addiction Risk Is Elevated

One underreported element of the Zyn litigation concerns the specific chemistry of nicotine delivery in oral pouches. Plaintiffs’ engineering and toxicology experts argue that Zyn is not merely equivalent to other nicotine products but is engineered for faster and more complete nicotine absorption than cigarettes.

The pH level of Zyn’s formula is elevated, typically alkaline, which increases the proportion of “free-base” nicotine in the product. Free-base nicotine crosses biological membranes more rapidly than the ionized form predominant in lower-pH products. Research cited in the Siegert complaint found that some nicotine pouches contain free-base nicotine proportions exceeding 95 percent, enabling rapid absorption through the gum and oral mucosa. The result, plaintiffs allege, is that users may absorb more nicotine per unit than they would from a cigarette, with the dose arriving more quickly, intensifying the addictive response and making dependence more likely after initial use.

Research published in the journal Frontiers in Cardiovascular Medicine documented that sustained nicotine exposure, regardless of delivery mechanism, contributes to endothelial dysfunction, a precursor to atherosclerosis, and increases sympathetic nervous system activation. For non-smoking teenagers, who have no pre-existing nicotine use, introducing a highly bioavailable nicotine delivery system creates new cardiovascular and neurological risk with no harm-reduction benefit whatsoever. The Harvard T.H. Chan School of Public Health explicitly stated that while Zyn may reduce harm for adult smokers switching from cigarettes, teens and young adults who do not smoke should avoid the product entirely.

What the Defendants Say

Philip Morris International and Swedish Match have consistently denied the core allegations. Their defense arguments across the pending litigation include the following positions.

On the “tobacco-free” label: the companies maintain that “tobacco-free” accurately describes the absence of tobacco leaf, which is the established industry and regulatory meaning of the term, and that consumers understand tobacco products and nicotine products to be distinct categories.

On marketing to youth: Philip Morris states that its formal marketing guidelines prohibit social media influencer use, require all advertising to target adults 21 and older, mandate the use of models and actors aged 35 or above, and include explicit restrictions against themes appealing to minors. The company cites its marketing practices as “setting the benchmark for the industry.”

On the FDA authorization: the FDA’s January 2025 marketing authorization, the first ever granted to a nicotine pouch product, is presented as affirmative regulatory validation that Zyn’s benefits to adult smokers outweigh its risks.

On nicotine content and addiction risk: the defendants have not disputed that Zyn contains addictive nicotine, which is disclosed on packaging. Their position is that nicotine addiction is a known and disclosed feature of any nicotine product, not a concealed defect.

Who Can File a Zyn Lawsuit

The consumer class action track covers anyone who purchased Zyn and may have been misled by its labeling or advertising. Those claims do not require proof of personal physical injury and are primarily economic: recovery of the price premium paid based on the deceptive “tobacco-free” claim or other misleading representations. The personal injury track requires documented harm: a diagnosis of nicotine addiction with medical records, cardiovascular findings, documented oral tissue changes, or mental health consequences tied to nicotine dependence.

The statute of limitations for consumer fraud claims and personal injury claims varies by state, typically running two to four years from discovery of the injury or the deceptive practice. Minors who were addicted to Zyn before age 18 may have additional time to file after reaching adulthood, as tolling provisions for minors apply in most jurisdictions. Consulting a product liability attorney early is advisable, as the Friedman trial date of December 2026 means the litigation timeline is advancing.

The Philip Morris Pattern — Why History Matters in These Cases

The lawsuits against Zyn do not emerge in a vacuum. Philip Morris International’s parent history with youth nicotine marketing forms an explicit part of the litigation narrative. Plaintiffs’ complaints reference decades of internal tobacco industry documents, made public through prior litigation and congressional investigations, showing that Philip Morris systematically studied adolescent psychology to design Marlboro advertising that appealed to the desire for independence, social status, and adult identity in teenagers. Internal documents from that era explicitly identified younger age brackets as growth markets.

The March 2024 class action complaint stated that Philip Morris “understands youth marketing practices better than almost any other company in the world, having for years profited by addicting kids to Marlboro cigarettes,” and that the company had “merely replaced Marlboro with Zyn.” This framing is legally significant because it supports the allegation of intentional targeting rather than incidental youth exposure, which bears on punitive damages and whether a pattern of conduct can be shown.

The tobacco industry’s historical playbook, use candy-adjacent flavors, lifestyle advertising, and the appearance of reduced harm, is now being deployed in the Zyn litigation as evidence that the current marketing strategy is not novel but a direct continuation of methods the industry developed specifically to recruit young, non-smoking customers. Similar to the allegations in the TikTok addiction lawsuit, where internal documents showed executives were aware of harm to young users but chose profit over protection, plaintiffs in the Zyn cases are seeking to show that Philip Morris understood exactly what it was doing when it positioned Zyn as a lifestyle product in the social media ecosystem where American teenagers spend their hours.

Read These

• TikTok youth addiction lawsuit
• Johnson and Johnson baby powder lawsuit
• AFFF firefighting foam cancer lawsuit
• Tampax tampon lawsuit
• Hernia mesh lawsuit

What This Lawsuit Teaches Consumers

The Zyn litigation is a case study in how a new product category escapes regulatory frameworks designed for its predecessors long enough to establish a user base before accountability arrives.

Nicotine pouches entered the U.S. market in 2014. The FDA did not complete its first premarket tobacco product application review for any nicotine pouch until January 2025, eleven years after the products went on sale. During that decade, Zyn grew from a niche product to one with over 350 million cans sold annually, capturing 70 percent market share, building a viral social media presence, and reaching nearly half a million American middle and high schoolers. The lawsuits now working through the courts are attempting to impose accountability for a period during which the regulatory review that should have preceded widespread marketing had simply not been completed.

The “tobacco-free” labeling question also carries a lesson that extends well beyond Zyn. Language that is technically defensible in a narrow legal sense can still be functionally misleading to ordinary consumers. A consumer who reads “tobacco-free” on a product and concludes the product therefore carries no tobacco-related health risks is not making an unreasonable inference. The lawsuits argue that inference was precisely what Philip Morris intended to create. Whether courts ultimately agree that the label crosses into illegal deception will turn on how state consumer protection laws define misleading representations and whether a reasonable consumer standard applies to the specific wording used.

The broader message is familiar from decades of tobacco litigation but newly relevant for every nicotine delivery product entering the market as a purported harm-reduction tool: “safer than cigarettes” is not the same as “safe,” and “tobacco-free” does not mean “risk-free.” Consumers, particularly those who have never used nicotine, face the greatest risk from nicotine pouches because they receive no harm-reduction benefit and take on the full burden of addiction risk from a baseline of zero dependence. The Harvard T.H. Chan School of Public Health put it plainly: teens and young adults who do not smoke or vape should not use Zyn. The lawsuits now proceeding toward trial will determine whether Philip Morris had a legal obligation to say the same, loudly, on the can.